About Cell IDx
Cell IDx is a company based in San Diego (United States) founded in 2012 was acquired by Leica Biosystems in November 2022. Cell IDx has raised $1.34 million across 2 funding rounds from investors including Leica Biosystems. Cell IDx offers products and services including Tissue Processors, Digital Pathology Scanners, and IHC Primary Antibodies. Cell IDx operates in a competitive market with competitors including HYCOR BioMedical, Exagen, Kypha, Lophius Biosciences and SmartHealth, among others.
- Headquarter San Diego, United States
- SectorsHealthcare
- Website cellidx.com
- Social LinkedIn Facebook YouTube
- Acquired by Leica Biosystems (Nov 2022)
- Legal Name Cell Idx, Inc
- Total Equity Funding$1.34M (USD)
in 2 rounds
- Latest Funding Round$1.34M (USD), Seed
Dec 2021
- Investors
- Acquired byLeica Biosystems
(Nov 2022)
Products & Services of Cell IDx
Cell IDx offers a comprehensive portfolio of products and services, including Tissue Processors, Digital Pathology Scanners, and IHC Primary Antibodies.
Devices for preparing tissue samples in diagnostics
Scanners for high-quality slide imaging in research
Antibodies for immunohistochemistry applications
Apps and channels of Cell IDx
its YouTube channel LeicaBiosystems has 2.04K subscribers and 30 videos.
Videos from Cell IDx
The most watched videos on Cell IDx's YouTube channel, LeicaBiosystems (2.04K subscribers). Click a video to play it here.
More on LeicaBiosystems.
Funding Insights of Cell IDx
Cell IDx has successfully raised a total of $1.34M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.34 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.34M
- Total Rounds 2
- Last Round Seed — $1.34M
- First Round $507,457
(May 2016)
All 2 funding rounds of Cell IDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2021 | $1.34M | Seed | – | – | – |
| May 2016 | $507,457 | Grant | – | – | – |
1 investors in total: 1 institutional.
Investors in Cell IDx
Cell IDx has secured backing from 1 investor. Prominent investors backing the company include Leica Biosystems.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provides tools for anatomic pathology, histology, and digital cancer diagnostics worldwide. | 1989 | leicabiosystems.com | Nussloch, Germany |
Investor details for Cell IDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cell IDx
2 people are tracked at Cell IDx (2 in leadership).
| Name | Role | Group |
|---|---|---|
David Schwartz | Co-Founder, CEO, CSO | Leadership |
Helen Snyder | Director of Business Development & Strategic Partnerships | Leadership |
Complete people profiles for Cell IDx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cell IDx
4 dated milestones of Cell IDx across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Cell IDx is founded.
- Funding First funding round of $507K.
- Funding Latest funding round, Seed, of $1.3M.
- Exit Acquired by Leica Biosystems.
Competitors of Cell IDx
Cell IDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HYCOR BioMedical, Exagen, Kypha, Lophius Biosciences and SmartHealth, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| hycorbiomedical.com | 1981 | Garden Grove, United States | $99.57M | – | Developer of diagnostic instruments and reagents for autoimmune diseases and allergies | |
| exagen.com | 2002 | Vista, United States | $110.23M | 204 | Diagnostic and monitoring solutions for autoimmune connective diseases are developed. | |
| kypha.net | 2009 | Saint Louis, United States | $16.76M | – | Diagnostic biomarker tests for inflammation and autoimmune diseases are developed. | |
| lophius.com | 2008 | Regensburg, Germany | $23.73M | 28 | T-cell-based diagnostics for infectious and immune diseases are developed. | |
| smarthealthdx.com | 1979 | Irvine, United States | $17.29M | – | Precision diagnostics for vascular, metabolic, and oncological diseases are developed. | |
| tbgbio.com | 1989 | Darra, Australia | – | – | Molecular diagnostics kits, instruments, and software are developed and manufactured. | |
| predictimmune.com | 2017 | Cambridge, United Kingdom | $18.32M | 15 | Tools for diagnosing immune-mediated inflammatory diseases are developed. | |
| sanodx.com | 2013 | Wellesley, United States | – | – | A point-of-care platform for chronic wound diagnostics is offered. | |
| immudex.com | 2009 | Copenhagen, Denmark | $16.35M | 42 | Provider of immune monitoring reagents and services for research and clinical use |
Detailed competitors of Cell IDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Cell IDx
10 companies that operate in the same segment as Cell IDx (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cell IDx
Cell IDx was founded in 2012 and raised its 1st funding round 4 years after it was founded.
Cell IDx is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Cell IDx is a funded company, having raised a total of $1.34M across 2 funding rounds to date. The company's 1st funding round was a Grant of $507.46K, raised on May 2016.
Cell IDx was founded in 2012 and is based in San Diego, United States. Operations focus on the biotechnology sector, where highly sensitive reagents for research and clinical immunohistochemistry, as well as other immunoassays, are developed. Products such as ultrapolymer enzyme conjugates, ultraplex immunohistochemistry kits, and ancillary reagents are offered. Biomolecules are also conjugated and immobilized with emphasis on high yields and activity retention.
Cell IDx's top competitors include Exagen, SmartHealth and HYCOR BioMedical.
Cell IDx offers Tissue Processors, Digital Pathology Scanners, and IHC Primary Antibodies.
Cell IDx has 1 investor. Key investors include Leica Biosystems.
Cell IDx operates through Cell Idx, Inc.
Yes. Cell IDx was acquired by Leica Biosystems in November 2022.